Valuation: Mabpharm Limited

Market Cap 1.42B 1.65B 210M 185M 173M 158M 296M 20.15B 304M 2.05B 800M 9.97B 790M 773M 34.46B P/E 2024
-8.48x
P/E 2025 44.9x
Enterprise Value 1.64B 1.9B 242M 213M 199M 182M 342M 23.22B 350M 2.36B 922M 11.49B 910M 891M 39.73B EV / Sales 2024
5.06x
EV / Sales 2025 3.2x
Free-Float
22.82%
Yield 2024 *
-
Yield 2025 -
1 week-1.23%
Current month-4.76%
1 month-4.76%
3 months-13.04%
6 months-24.53%
Current year-20.00%
1 week 0.4
Extreme 0.395
0.41
1 month 0.36
Extreme 0.365
0.44
Current year 0.31
Extreme 0.31
0.81
1 year 0.31
Extreme 0.31
0.88
3 years 0.25
Extreme 0.25
0.94
5 years 0.25
Extreme 0.25
1.28
10 years 0.25
Extreme 0.25
1.8
Manager TitleAgeSince
Chief Executive Officer 57 2020-10-27
Corporate Officer/Principal 49 2023-11-30
Corporate Officer/Principal 53 2018-08-02
Director TitleAgeSince
Director/Board Member 57 2018-07-19
Director/Board Member 49 2018-07-19
Chairman 60 2018-07-19
Date Insider Type Main position Quantity % Market Cap.
2/10/23 Other

Director

75,192 0.0018%
Change 5-day change 1-year change 3-year change Capi.($)
0.00%-1.23%-24.53%-42.86% 210M
+0.47%+2.27%+50.78%+69.72% 55.01B
+2.83%+0.04%+38.07%+82.59% 54.24B
+1.04%+1.56%-16.34%-14.34% 23.38B
-0.28%-2.79%-1.27%+369.31% 22.57B
+2.07%+1.44%+23.06%-9.05% 20.19B
-2.15%-2.30%+27.27%-33.01% 17.86B
-2.14%-2.72%+30.26%+536.72% 15.5B
-3.14%-8.09%+160.68%+292.18% 14.2B
-1.10%+1.82%+51.54%+184.02% 14.2B
Average -0.14%-0.62%+33.95%+143.53% 23.74B
Weighted average by Cap. +0.52%-0.20%+37.40%+128.98%

Financials

2024 2025
Net sales 258M 299M 38.14M 33.51M 31.28M 28.71M 53.74M 3.65B 55.06M 371M 145M 1.81B 143M 140M 6.25B 646M 748M 95.42M 83.85M 78.26M 71.83M 134M 9.14B 138M 928M 363M 4.52B 358M 350M 15.64B
Net income -128M -148M -18.9M -16.6M -15.5M -14.22M -26.63M -1.81B -27.28M -184M -71.87M -896M -70.95M -69.41M -3.1B 57.13M 66.18M 8.44M 7.41M 6.92M 6.35M 11.89M 808M 12.18M 82.07M 32.09M 400M 31.68M 30.99M 1.38B
Net Debt 222M 257M 32.82M 28.84M 26.92M 24.71M 46.25M 3.14B 47.39M 319M 125M 1.56B 123M 121M 5.38B 217M 252M 32.12M 28.22M 26.34M 24.18M 45.26M 3.08B 46.37M 312M 122M 1.52B 121M 118M 5.26B
Logo Mabpharm Limited
Mabpharm Ltd is an investment holding company primarily engaged in the research, development and production of monoclonal antibody drugs for cancers and autoimmune diseases. The Company’s main products include CMAB009 Enlituo (cetuximab β injection), CMAB007 Aomaishu (Omalizumab α for Injection), CMAB008 Leiting (infliximab for injection) and other products. The Company’s products are mainly used for colorectal cancer, asthma, urticaria, rheumatoid arthritis, ulcerative colitis in adults and other diseases. The Company is also engaged in the transfer of intellectual property. The Company mainly conducts its business in the domestic market.
Employees
389
Date Price Change Volume
26-07-29 HK$0.4000 0.00% 0
26-07-28 HK$0.4000 0.00% 0
26-07-27 HK$0.4000 -2.44% 82,000
26-07-24 HK$0.4100 0.00% 0
26-07-23 HK$0.4100 0.00% 0
  1. Stock Market
  2. Stocks
  3. 2181 Stock